secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2023-08-30T23:59:59+00:00
Accession:  0001601485-23-000055
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Elicio Therapeutics director Assaf Segal resigns effective August 28, 2023
--------------------------------------------------------------------------

- Assaf Segal resigned from the Board of Elicio Therapeutics, effective immediately on August 28, 2023.
- Resignation follows his planned departure as CEO of Clal Biotechnology Industries, not due to any disagreement.
- No replacement named; the Board continues with remaining members.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148523000055/0001601485-23-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148523000055/angn-20230828.htm
  HTML page:      https://secwatch.observer/filing/0001601485-23-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer